Abcam’s (ABC) “Hold” Rating Reaffirmed at Peel Hunt
Other equities research analysts have also recently issued reports about the company. Numis Securities reaffirmed a hold rating on shares of Abcam in a research note on Tuesday, September 11th. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of Abcam in a research note on Wednesday, January 2nd.
Shares of ABC stock opened at GBX 1,167 ($15.25) on Monday. Abcam has a 52-week low of GBX 9.73 ($0.13) and a 52-week high of GBX 1,290 ($16.86).
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
Featured Article: Mutual Funds
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.